Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134558

Published: 2020

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3936.

https://doi.org/10.1182/blood-2019-131759

Published: 2019

Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani

Blood (2019) 134 (Supplement_1): 4360.

https://doi.org/10.1182/blood-2019-124135

Published: 2019

Journal Articles

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Malathi Kandarpa, PhD, Kristen Pettit, MD, Tingting Qin, PhD, Yi-Mi Wu, PhD, Dan Robinson, PhD, Maureen Sartor, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 4212.

https://doi.org/10.1182/blood-2019-128301

Published: 2019

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

Malathi Kandarpa, PhD, Kristen Pettit, MD, Yi-Mi Wu, PhD, Qing Li, MD, Robert Lonigro, Dan Robinson, PhD, Luke F. Peterson, PhD, Philip S Boonstra, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2018) 132 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2018-99-113418

Published: 2018

Journal Articles

The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System

Benjamin Garmezy, MD, Philip S Boonstra, PhD, Malathi Kandarpa, PhD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 2929.

https://doi.org/10.1182/blood.V130.Suppl_1.2929.2929

Published: 2017

Journal Articles

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Jagoda Jasielec, Dominik Dytfeld, Kent A. Griffith, Kathryn McDonnell, Daniel Lebovic, Malathi Kandarpa, PhD, Tara Anderson, Melissa Mietzel, Malek Faham, Liana Lee, Joan Levy, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark Kaminski, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2127.

https://doi.org/10.1182/blood.V124.21.2127.2127

Published: 2014

Journal Articles

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Martin van Vliet, PhD, Jagoda Jasielec, MD, Dominik Dytfeld, MD PhD, Ravi Vij, MD, Belinda Dumee, BSc, Lizanne Bosman, BSc, Leonie C.M. deBest, MSc, Mattina Alonge, MS, Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Kathryn McDonnell, BS, Kent A. Griffith, Erik H van Beers, PhD, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2141.

https://doi.org/10.1182/blood.V124.21.2141.2141

Published: 2014

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

Shaun Rosebeck, PhD, Malathi Kandarpa, PhD, Mattina M. Alonge, Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Sean P Maxwell, Stephanie J Kraftson, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 279.

https://doi.org/10.1182/blood.V122.21.279.279

Published: 2013

Journal Articles

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Daniel Lebovic, MD, Mark S. Kaminski, MD, Tara B. Anderson, Kristen Detweiler-Short, Kent A. Griffith, Terri L. Jobkar, BSN, Malathi Kandarpa, PhD, Andrzej Jakubowiak, MD, PhD

Blood (2012) 120 (21): 1854.

https://doi.org/10.1182/blood.V120.21.1854.1854

Published: 2012

Journal Articles

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Luke F. Peterson, PhD, Hanshi Sun, PhD, Yihong Liu, PhD, Malathi Kandarpa, PhD, Diane Giannola, Jessica Mercer, PhD, Hollis D. Showalter, Ph.D., Andrzej Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas J. Donato, PhD

Blood (2012) 120 (21): 2936.

https://doi.org/10.1182/blood.V120.21.2936.2936

Published: 2012

Journal Articles

CRM1 Is Highly Expressed in Myeloma Plasma Cells and Its Inhibition by KPT-SINE Induces Cytotoxicity by Increasing p53 in the Nucleus of Multiple Myeloma (MM) Cells

Malathi Kandarpa, PhD, Stephanie J Kraftson, Sean P Maxwell, Dilara McCauley, PhD, Sharon Shacham, PhD, MBA, Michael Kauffman, Andrzej J Jakubowiak, MD, PhD

Blood (2011) 118 (21): 1852.

https://doi.org/10.1182/blood.V118.21.1852.1852

Published: 2011

Journal Articles

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Luke F. Peterson, PhD, Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Malathi Kandarpa, PhD, Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2011) 118 (21): 1835.

https://doi.org/10.1182/blood.V118.21.1835.1835

Published: 2011

Journal Articles

Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone

Dominik Dytfeld, MD, PhD, Malathi Kandarpa, PhD, John R Strahler, PhD, Dattatreya Mellacheruvu, Suchitra Subramani, Stephanie J Kraftson, Lambert Ngoka, PhD, Alexey Nesvizhskii, PhD, Arun Sreekumar, PhD, Paul G Richardson, MD, Andrzej J Jakubowiak, MD, PhD

Blood (2010) 116 (21): 618.

https://doi.org/10.1182/blood.V116.21.618.618

Published: 2010

Journal Articles

Proteomic Signature Predicting Achievement of Very Good Partial Response In Patients with Multiple Myeloma Based On Complementary Label-Free and iTRAQ Quantitative Proteome Analysis

Blood (2010) 116 (21): 1902.

https://doi.org/10.1182/blood.V116.21.1902.1902

Published: 2010

Journal Articles

Proteomic Profiling of Multiple Myeloma Plasma Cells and Normal Plasma Cells Reveals Differential Expression of Clu1 and Basp1 Proteins

Dominik Dytfeld, MD, PhD, Malathi Kandarpa, PhD, Stephanie J Kraftson, John R Strahler, PhD, Dattatreya Mellacheruvu, Suchitra Subramani, Alexey Nesvizhskii, PhD, Andrzej J Jakubowiak, MD, PhD

Blood (2010) 116 (21): 4034.

https://doi.org/10.1182/blood.V116.21.4034.4034

Published: 2010

NARROW

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity

The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System

Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)

Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM)

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

CRM1 Is Highly Expressed in Myeloma Plasma Cells and Its Inhibition by KPT-SINE Induces Cytotoxicity by Increasing p53 in the Nucleus of Multiple Myeloma (MM) Cells

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone

Proteomic Signature Predicting Achievement of Very Good Partial Response In Patients with Multiple Myeloma Based On Complementary Label-Free and iTRAQ Quantitative Proteome Analysis

Proteomic Profiling of Multiple Myeloma Plasma Cells and Normal Plasma Cells Reveals Differential Expression of Clu1 and Basp1 Proteins

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only